Paul K Wotton's Net Worth
$6.38 Million
Who is Paul K Wotton?
Paul K Wotton has an estimated net worth of $6.38 Million. This is based on reported shares across multiple companies, which include Vericel Corp, ANTARES PHARMA, INC., Ocata Therapeutics, Inc., and GENAERA CORP.
SEC CIK
Paul K Wotton's CIK is 0001300997
Past Insider Trading and Trends
2013 was Paul K Wotton's most active year for acquiring shares with 12 total transactions. Paul K Wotton's most active month to acquire stocks was the month of April. 2013 was Paul K Wotton's most active year for disposing of shares, totalling 18 transactions. Paul K Wotton's most active month to dispose stocks was the month of December. 2021 saw Paul K Wotton paying a total of $637,612.50 for 54,600 shares, this is the most they've acquired in one year. In 2016 Paul K Wotton cashed out on 577,500 shares for a total of $2,358,750.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Vericel Corp (VCEL) Snapshot price: $44.05
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +11.94% | 3.2K |
—
|
—
| 30K |
May 1
| |||
Form 4
| -15.72% | -5.00K |
$37.31 | -$186,550.00 | 26.8K |
Dec 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 3
| |||
Form 4
| +8.90% | 2.6K |
—
|
—
| 31.8K |
Apr 27
| |||
Form 4
| +9.77% | 2.6K |
—
|
—
| 29.2K |
Apr 27
| |||
Form 4
| -15.82% | -5.00K |
$50.52 | -$252,611.00 | 26.6K |
May 14
| |||
Form 4
| +802.91% | 28.1K |
$32.25 | -$143,843.39 | 31.6K |
May 11 - May 12
| |||
Form 4
| +100.00% | 1.75K |
—
|
—
| 3.5K |
Apr 28
| |||
Form 4
|
∞
| 1.75K |
—
|
—
| 1.75K |
Apr 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 1
| |||
Form 4
|
—
|
0
|
$9.74 | -$318,868.00 |
0
|
Scheduled
|
Jan 2
| ||
Form 4
|
—
|
0
|
$7.74 | -$259,400.00 |
0
|
Scheduled
|
Jun 18
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 4
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ANTARES PHARMA, INC. No price found
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +39.81% | 266.99K |
—
|
—
| 937.73K |
May 29
| |||
Form 4
| +1.05% | 7K |
$4.85 | -$16,048.65 | 670.73K |
Feb 20
| |||
Form 4
| -6.35% | -45.00K |
$4.45 | -$48,950.00 | 663.73K |
Feb 11
| |||
Form 4
|
—
|
0
|
$2.80 | -$105,307.94 | 708.73K |
Scheduled
|
Jan 15
| ||
Form 4
|
—
|
0
|
$2.25 | -$224,594.86 | 708.73K |
Scheduled
|
Dec 6 - Dec 9
| ||
Form 4
|
—
|
0
|
$2.35 | -$129,010.00 | 708.73K |
Scheduled
|
Oct 1
| ||
Form 4
|
—
|
0
|
$2.46 | -$136,878.00 | 708.73K |
Scheduled
|
Sep 3
| ||
Form 4
|
—
|
0
|
$2.46 | -$137,091.50 | 708.73K |
Scheduled
|
Aug 1
| ||
Form 4
|
—
|
0
|
$2.32 | -$127,473.50 | 708.73K |
Scheduled
|
Jul 1
| ||
Form 4
|
—
|
0
|
$2.26 | -$438,637.50 | 708.73K |
Scheduled
|
Jun 3
| ||
Form 4
| +35.37% | 185.19K |
—
|
—
| 708.73K |
May 22
| |||
Form 4
|
—
|
0
|
$2.27 | -$35,350.00 | 523.55K |
Scheduled
|
May 6
| ||
Form 4
|
—
|
0
|
$2.26 | -$87,800.00 | 537.39K |
Scheduled
|
Jan 8
| ||
Form 4
|
—
|
0
|
$2.25 | -$87,507.50 | 537.39K |
Scheduled
|
Dec 4
| ||
Form 4
| +11.35% | 54.77K |
—
|
—
| 537.39K |
Jul 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
| +1.46% | 6.95K |
—
|
—
| 482.62K |
Feb 10
| |||
Form 4
| +10.49% | 45.16K |
—
|
—
| 475.67K |
Sep 9
| |||
Form 4
| +18.25% | 68K |
—
|
—
| 440.68K |
May 17
| |||
Form 4
| +4.89% | 17.37K |
—
|
—
| 372.68K |
Apr 7
| |||
Form 4
| +17.36% | 52.55K |
—
|
—
| 355.31K |
Feb 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 11
| |||
Form 4
| +3.30% | 10K |
$1.50 | $15,000.00 | 312.94K |
Aug 24
| |||
Form 4
| +21.62% | 53.85K |
—
|
—
| 302.94K |
Feb 22
| |||
Form 4
| +11.16% | 25K |
—
|
—
| 249.09K |
Nov 12
| |||
Form 4
| +28.72% | 50K |
—
|
—
| 224.09K |
Aug 12
| |||
Form 4
| +12.98% | 20K |
$0.40 | $8,051.00 | 174.09K |
Mar 30
| |||
Form 4
| +19.37% | 25K |
$0.48 | $12,000.00 | 154.09K |
Nov 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 20
| |||
Form 4
| +343.75% | 100K |
—
|
—
| 129.09K |
Aug 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 4
| +45.46% | 9.09K |
—
|
—
| 29.09K |
May 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ocata Therapeutics, Inc. No price found
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -277.50K |
$8.50 | -$2,358,750.00 |
0
|
Feb 10
| |||
Form 4
| -10.83% | -32.50K |
$4.23 | -$137,475.00 | 267.5K |
Jul 30
| |||
Form 4
| +3.33% | 10K |
—
|
—
| 310K |
Mar 5
| |||
Form 4
|
∞
| 30M |
—
|
—
| 30M |
Jul 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GENAERA CORP No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||